8-K: Imunon Appoints New Interim CFO Amidst CFO Retirement

Imunon, Inc. announced the retirement of its interim Chief Financial Officer, Jeffrey Church, effective July 1, 2026, and the appointment of Josh Blacher as his successor.

Summary

• Imunon, Inc. is reporting a change in its Chief Financial Officer position.
• Jeffrey Church, who served as interim CFO since January 2026, will retire effective July 1, 2026.
• Mr. Church will continue to provide services to the company as a consultant under an amended agreement, receiving a monthly retainer of $10,000.
• Josh Blacher has been appointed as the new interim Chief Financial Officer, effective July 1, 2026.
• Mr. Blacher will serve as the principal financial officer and principal accounting officer.
• He is engaged through a master services agreement with Danforth Health, Inc., a financial advisory firm.
• The company will pay Danforth Health, Inc. $475 per hour for Mr. Blacher's services.
• Mr. Blacher brings extensive experience in financial leadership roles at various life sciences and public companies.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it involves a planned retirement and a structured appointment of a new interim CFO with relevant experience, rather than an unexpected departure or a sign of immediate financial distress.

Positives

• Smooth transition plan in place with the outgoing interim CFO continuing in a consulting role.
• Appointment of Josh Blacher brings significant financial expertise from prior roles at life sciences companies.
• Mr. Blacher has experience as CFO for other public companies, including BullFrog AI Holdings, Inc., Inmed Pharmaceuticals, Therapix Biosciences, and Galmed Pharmaceuticals.
• The company has secured services through a specialized financial advisory firm, Danforth Health, Inc.

Negatives

• The company is experiencing a change in its interim Chief Financial Officer role.
• The company will incur hourly fees for the new interim CFO's services, at a rate of $475 per hour.

Risks

• Potential disruption during the transition of financial leadership.
• Reliance on external consulting services for key financial roles may present ongoing costs and integration challenges.
• The effectiveness of the new interim CFO in navigating Imunon's specific financial landscape.

Future Outlook

No specific forward-looking financial guidance or outlook is provided in this filing. The focus is on executive personnel changes.

Management Comments

• Jeffrey Church informed Imunon, Inc. of his intent to retire from the position of interim Chief Financial Officer.
• Mr. Church's departure is due to retirement and is without any disagreements with management.

Industry Context

StockSavvy.ai notes that frequent changes in interim financial leadership, particularly in the life sciences sector, can sometimes indicate underlying financial pressures or a strategic search for more permanent financial expertise. The engagement of a specialized firm like Danforth Health suggests a deliberate approach to filling this critical role.

Management Changes

Stakeholder Impact

• Shareholders: The change in CFO may lead to a period of adjustment, but the appointment of an experienced interim CFO is intended to maintain financial oversight.
• Employees: The transition may cause some uncertainty, but the continued involvement of the former interim CFO in a consulting capacity could provide continuity.
• Creditors: The company's financial reporting and management remain under the purview of a designated principal financial and accounting officer.

Next Steps

• Josh Blacher to assume duties as interim Chief Financial Officer, principal financial officer, and principal accounting officer effective July 1, 2026.
• Jeffrey Church to continue providing consulting services to Imunon, Inc. under the amended consulting agreement.

Key Dates

Keywords

Imunon, 8-K, CFO, Chief Financial Officer, Retirement, Appointment, Josh Blacher, Jeffrey Church, Danforth Health, Consulting Agreement, Financial Officer, Accounting Officer